A COX-2 inhibitor combined with chemoradiation of locally advanced rectal cancer: a phase II trial
| Autor: | Claus Bisgaard, John Mortensen, Vagn Ove Bendtsen, Anders Jakobsen, Søren Rafael Rafaelsen, Jan Lindebjerg |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Oncology
Adult Male medicine.medical_specialty Colorectal cancer Biopsy Adenocarcinoma Gastroenterology law.invention Endosonography Randomized controlled trial law Internal medicine Antineoplastic Combined Chemotherapy Protocols Medicine Humans Cyclooxygenase Inhibitors Uracil Aged Neoplasm Staging Tegafur Sulfonamides Dose-Response Relationship Drug business.industry Rectal Neoplasms Cancer Dose-Response Relationship Radiation Hepatology Middle Aged medicine.disease Magnetic Resonance Imaging Clinical trial Treatment Outcome Cardiovascular Diseases Celecoxib COX-2 inhibitor Pyrazoles Female business Chemoradiotherapy medicine.drug |
| Zdroj: | Jakobsen, A, Mortensen, J P, Bisgaard, C, Lindebjerg, J, Rafaelsen, S R & Bendtsen, V O 2008, ' A COX-2 inhibitor combined with chemoradiation of locally advanced rectal cancer : a phase II trial ', International Journal of Colorectal Disease, vol. 23, no. 3, pp. 251-5 . https://doi.org/10.1007/s00384-007-0407-7 |
| ISSN: | 0179-1958 |
| DOI: | 10.1007/s00384-007-0407-7 |
| Popis: | The aim of this study was to investigate the possible effect of a COX-2 inhibitor in addition to chemoradiation of locally advanced rectal cancer.The study included 35 patients with rectal adenocarcinoma. All patients had a tumor localisedor=10 cm from the anal verge and a circumferential marginor=5 mm on a magnetic resonance scan. The patients were scheduled to receive external radiation with a tumor dose of 60 Gy supplemented with an endorectal boost of 5 Gy. Concurrent with radiation, the patients received uracil-tegafur 300 mg/m(2) daily. Celexocib was scheduled throughout the radiation period in a dose of 400 mg x 2 daily.A macular papular rash was seen in 17 (49%) of the patients leading to stop of medication with celecoxib. Thirty-three patients were operated, and all patients responded to treatment. Complete pathological remission was found in 21% of the patients and further 24% had only microscopic residual tumor cells. The results did not suggest any difference according to the accomplishment of the COX-2 medication.The addition of a COX-2 inhibitor to chemotherapy-enhanced radiation treatment of rectal cancer was not feasible due to a high incidence of rash in the present study. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink